ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1699

RAPID3 Near Remission Shows Good Agreement with Minimal Disease Activity Criteria in Psoriatic Arthritis

Laura C. Coates1,2, William Tillett3,4, Theodore Pincus5, Arthur Kavanaugh6 and Philip S. Helliwell7, 1Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 2NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, 3Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom, 4Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, 5Rheumatology, Rush University Medical Center, Chicago, IL, 6Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, CA, 7NIHR-Leeds Musculoskeletal Biomedical Research Unit, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Outcome measures, psoriatic arthritis and remission

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2016

Title: Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster II: Psoriatic Arthritis

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:  RAPID3 (routine assessment of patient index data) is a patient self-report index which is feasible in busy clinical settings to assess severity and change in clinical status in many rheumatic diseases, including RA, OA, gout, AxSpA. RAPID3 (0-30) includes 3 0-10 measures: a health assessment questionnaire (HAQ) or its multidimensional version (MDHAQ) measuring physical function and two 0-10 visual analogue scales (VAS) for pain and patient global estimate. A score of ≤3 (of 30) identifies near remission (NR) in rheumatoid arthritis. RAPID3 is correlated significantly with other PsA measures; a RAPID3Ps has also been investigated with the addition of a skin VAS for PsA. The Minimal Disease Activity (MDA) criteria for PsA require achievement of 5 of 7 cutpoints in 7 measures: the three RAPID measures; tender joint count (TJC); swollen joint count (SJC); enthesitis count and skin measure. Our aim was to compare patients achieving RAPID3 and RAPID3Ps near remission and MDA criteria in PsA in individual patients in the Tight Control of Psoriatic Arthritis (TICOPA) trial.

Methods: Data from TICOPA were analysed to identify patients achieving RAPID3 and RAPID3Ps NR, and the patients were compared to those achieving the MDA criteria. MDA was achieved if patients achieved 5 of the 7 following cut points: TJC ≤1; SJC ≤1; enthesitis ≤1; PASI ≤1; HAQ function ≤0.5; global VAS ≤20 and pain VAS ≤15. Frequency of residual active disease in the RAPID3 NR states was investigated. A measure of acute phase response is not included in either measure, but CRP levels were assessed to recognize whether an active acute phase response was missed.

Results: The percentage exact agreement (PEA) between RAPID3 NR and MDA was 83.8, 89.8, 87.1, 85.2 at 12, 24, 36, 48 weeks respectively. Adding the skin component to create RAPID3Ps and using the equivalent NR cutpoint (4/40) led to PEA of 85.1, 88.0, 88.5 and 85.1 respectively. Very few patients (2.2-3.8%) were in RAPID3NR but not MDA due to high physician assessed outcomes. For patients in RAPID3NR at the end of the study, residual disease activity is shown in the table. Levels of skin disease in this population were very low with PASI of 0 in 94% of these patients.

Conclusion:  RAPID3NR and RAPID3PsNR shows good agreement with the MDA criteria in PsA. The addition of a psoriasis measure did not change the results meaningfully in this population, but may be more infortative in patients with more severe skin disease. The RAPID3 NR definition does allow significant residual disease in a few patients but may be useful as an adjunct to physician examination when monitoring disease activity. 

    RAPID3 NR n (%) (n=67) RAPID3Ps NR n (%)(n=67)
PASDAS Mean (SD) 1.82 (0.70) 1.79 (0.71)
Tender joint count 0 38 (56.7) 38 (56.7)
1 11 (16.4) 10 (14.9)
2 5 (7.5) 6 (9.0)
3 2 (3.0) 2 (3.0)
4 5 (7.5) 5 (7.5)
5 1 (1.5) 1 (1.5)
7 3 (4.5) 3 (4.5)
8 2 (3.0) 2 (3.0)
Swollen joint count 0 49 (73.1) 50 (74.6)
1 9 (13.4) 7 (10.4)
2 5 (7.5) 5 (7.5)
3 1 (1.5) 1 (1.5)
4 2 (3.0) 3 (4.5)
5 1 (1.5) 1 (1.5)
Enthesitis count 0 48 (71.6) 49 (73.1)
1 8 (11.9) 7 (10.4)
2 7 (10.4) 7 (10.4)
3 3 (4.5) 3 (4.5)
7 1 (1.5) 1 (1.5)
Dactylitis count 0 62 (92.5) 63 (94)
1 1 (1.5) 1 (1.5)
2 3 (4.5) 3 (4.5)
3 1 (1.5) 0 (0)
PASI 0 63 (94.0) 63 (94.0)
0.3 1 (1.5) 1 (1.5)
0.6 1 (1.5) 1 (1.5)
0.8 0 (0) 1 (1.5)
3 2 (3.0) 1 (1.5)
CRP Normal (<5mg/dl) 51 (76.1) 50 (74.6)
Raised 15 (22.4) 15 (22.4)
Missing 1 (1.5) 2 (3.0)


Disclosure: L. C. Coates, None; W. Tillett, None; T. Pincus, Health Report Services Inc., 4; A. Kavanaugh, None; P. S. Helliwell, None.

To cite this abstract in AMA style:

Coates LC, Tillett W, Pincus T, Kavanaugh A, Helliwell PS. RAPID3 Near Remission Shows Good Agreement with Minimal Disease Activity Criteria in Psoriatic Arthritis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/rapid3-near-remission-shows-good-agreement-with-minimal-disease-activity-criteria-in-psoriatic-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/rapid3-near-remission-shows-good-agreement-with-minimal-disease-activity-criteria-in-psoriatic-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology